iShares Biotechnology ETF
893 hedge funds and large institutions have $5.16B invested in iShares Biotechnology ETF in 2024 Q3 according to their latest regulatory filings, with 81 funds opening new positions, 243 increasing their positions, 319 reducing their positions, and 73 closing their positions.
11% more first-time investments, than exits
New positions opened: 81 | Existing positions closed: 73
0% less funds holding
Funds holding: 894 → 893 (-1)
2% less capital invested
Capital invested by funds: $5.28B → $5.16B (-$124M)
3.33% less ownership
Funds ownership: 70.9% → 67.57% (-3.3%)
9% less funds holding in top 10
Funds holding in top 10: 11 → 10 (-1)
24% less repeat investments, than reductions
Existing positions increased: 243 | Existing positions reduced: 319
39% less call options, than puts
Call options by funds: $496M | Put options by funds: $810M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BNP Paribas Financial Markets
Paris,
France
|
+$78M |
| 2 |
Jane Street
New York
|
+$65.4M |
| 3 |
Morgan Stanley
New York
|
+$63.5M |
| 4 |
BlackRock
New York
|
+$57.3M |
| 5 |
Barclays
London,
United Kingdom
|
+$45.7M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Goldman Sachs
New York
|
-$259M |
| 2 |
JP Morgan Chase
New York
|
-$208M |
| 3 |
Citigroup
New York
|
-$160M |
| 4 |
Bank of America
Charlotte,
North Carolina
|
-$53.2M |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$31.5M |
IBB Hedge Fund Activity: Q3 2024 in Review
893 of the 6,964 institutional investors tracked by Wall St. Rank reported a position in iShares Biotechnology ETF (IBB) for Q3 2024, worth a combined $5.16B — down 2.3% from $5.28B a quarter earlier.
Buyers outnumbered sellers: 81 funds opened new IBB positions and 73 closed out — a net gain of 8 holders — while 243 added to existing stakes and 319 trimmed.
The largest buyer was BNP Paribas Financial Markets, adding an estimated $78M. The largest seller was Goldman Sachs, cutting an estimated $259M.
- 893 institutional investors held iShares Biotechnology ETF (IBB) as of Q3 2024, down from 894 in Q2 2024.
- Funds reported $5.16B of iShares Biotechnology ETF stock for Q3 2024, down 2.3% quarter-over-quarter.
- 81 funds opened new iShares Biotechnology ETF positions in Q3 2024 and 73 closed out, a net change of +8 holders.
- The largest iShares Biotechnology ETF buyer in Q3 2024 was BNP Paribas Financial Markets, an estimated $78M added.
- The largest iShares Biotechnology ETF seller in Q3 2024 was Goldman Sachs, an estimated $259M sold.
Based on aggregated 13F filings for Q3 2024.